Chou Associates Management buys $35,433,185 stake in Valeant Pharmaceuticals Intl Inc (VRX)

Valeant Pharmaceuticals Intl Inc (VRX) : Chou Associates Management scooped up 470,000 additional shares in Valeant Pharmaceuticals Intl Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 1,446,843 shares of Valeant Pharmaceuticals Intl Inc which is valued at $35,433,185.Valeant Pharmaceuticals Intl Inc makes up approximately 12.52% of Chou Associates Management’s portfolio.

Other Hedge Funds, Including , Chicago Partners Investment Group boosted its stake in VRX in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 250 shares of Valeant Pharmaceuticals Intl Inc which is valued at $6,123.Oakworth Capital boosted its stake in VRX in the latest quarter, The investment management firm added 350 additional shares and now holds a total of 354 shares of Valeant Pharmaceuticals Intl Inc which is valued at $8,078.Academy Capital Management Inctx boosted its stake in VRX in the latest quarter, The investment management firm added 309,680 additional shares and now holds a total of 573,321 shares of Valeant Pharmaceuticals Intl Inc which is valued at $13,083,185. Valeant Pharmaceuticals Intl Inc makes up approx 3.37% of Academy Capital Management Inctx’s portfolio.Ruane Cunniff Goldfarb Inc reduced its stake in VRX by selling 29,862,007 shares or 98.53% in the most recent quarter. The Hedge Fund company now holds 446,442 shares of VRX which is valued at $10,491,387. Valeant Pharmaceuticals Intl Inc makes up approx 0.10% of Ruane Cunniff Goldfarb Inc’s portfolio. Hartford Financial Management added VRX to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $2,286.

Valeant Pharmaceuticals Intl Inc opened for trading at $25.63 and hit $26.91 on the upside on Monday, eventually ending the session at $26.59, with a gain of 6.70% or 1.67 points. The heightened volatility saw the trading volume jump to 2,88,95,668 shares. Company has a market cap of $9,241 M.

On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $1.48. The company had revenue of $2420.20 million for the quarter, compared to analysts expectations of $2451.77 million. The company’s revenue was down -11.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $2.14 EPS.

Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Company shares were Upgraded by Mizuho on Aug 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $11 .Company shares were Reiterated by Piper Jaffray on Aug 10, 2016 to “Underweight”, Firm has raised the Price Target to $ 22 from a previous price target of $19 .Company shares were Reiterated by RBC Capital Mkts on Aug 10, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 36 from a previous price target of $31 .

Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.

Leave a Reply

Valeant Pharmaceuticals Intl Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Valeant Pharmaceuticals Intl Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.